Bortezomib with HIG-dose dexamethasone as first line therapy in patients with multiple myeloma candidates to high-dose therapy

被引：0

作者：

Corso, Alessandro ^{[1
]}

Barbarano, Luciana ^{[2
]}

Mangiacavalli, Silvia ^{[1
]}

Montalbetti, Luigi

Brasca, Paola ^{[2
]}

Zappasodi, Patrizia ^{[1
]}

Carella, Angelo ^{[3
]}

Spriano, Mauro ^{[3
]}

Alessandrino, Emilio Paolo ^{[1
]}

Cairoli, Roberto ^{[2
]}

Petro, Daniela ^{[2
]}

Varettoni, Marzia ^{[1
]}

Bernasconi, Paolo ^{[1
]}

Lazzarino, Mario ^{[1
]}

Morra, Enrica ^{[2
]}

机构：

[1] Univ Pavia, Fdn IRCCS, Policlin San Matteo, Div Hematol, I-27100 Pavia, Italy

[2] Osped Ca Granda, Div Hematol, Milan, Italy

[3] Osped San Martino Genova, Div Hematol, Genoa, Italy

来源：

BLOOD | 2007年 / 110卷 / 11期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3595

引用

页码：1051A / 1052A

页数：2

共 50 条

[1] Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
Richardson, PG
Sonneveld, P
Schuster, MW
Irwin, D
Stadtmauer, EA
Facon, T
Harousseau, JL
Ben-Yehuda, D
Lonial, S
Goldschmidt, H
Reece, D
San-Miguel, JF
Bladé, J
Boccadoro, M
Cavenagh, J
Dalton, WS
Boral, AL
Esseltine, DL
Porter, JB
Schenkein, D
Anderson, KC
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (24): : 2487 - 2498
[2] The role of bortezomib in myeloma patients eligible for high-dose therapy
Jagannath, S.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 29 - 30
[3] High-dose therapy in multiple myeloma
Harousseau, JL
ANNALS OF ONCOLOGY, 2002, 13 : 49 - 54
[4] High-dose therapy in multiple myeloma
Dimopoulos, MA
BRITISH JOURNAL OF HAEMATOLOGY, 1998, 102 (01) : 142 - 143
[5] BORTEZOMIB IN COMBINATION WITH DEXAMETHASONE OVERCOMES THE NEED FOR ADDITIONAL CHEMOTHERAPY PRIOR TO HIGH-DOSE THERAPY WITH AUTOTRANSPLANT IN PATIENTS WITH MULTIPLE MYELOMA
Corso, A.
Barbarano, L.
Mangiacavalli, S.
Montalbetti, L.
Cafro, A. M.
Carella, A. M.
Spriano, M.
Alessandrino, P. E.
Grillo, G.
Varettoni, M.
Bernasconi, P.
Lazzarino, M.
Morra, E.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 158 - 158
[6] Is bortezomib superior to high-dose dexamethasone for the treatment of relapsed multiple myeloma?
Robert Z Orlowski
Nature Clinical Practice Oncology, 2006, 3 : 16 - 17
[7] Is bortezomib superior to high-dose dexamethasone for the treatment of relapsed multiple myeloma?
Orlowski, RZ
NATURE CLINICAL PRACTICE ONCOLOGY, 2006, 3 (01): : 16 - 17
[8] Gene expression profiles as prognostic factors for high-dose therapy and bortezomib in patients with multiple myeloma
Broyl, A.
Hose, D.
de Knegt, Y.
Lokhorst, H.
Goldschmidt, H.
Sonneveld, P.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 257 - 257
[9] Gene expression profiles as prognostic factors for high-dose therapy and bortezomib in patients with multiple myeloma
Broyl, A.
Hose, D.
De Knegt, Y.
Lokhorst, H.
Goldschmidt, H.
Sonneveld, P.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 65 - 65
[10] First Line Therapy in Multiple Myeloma: VAD vs Bortezomib -Dexamethasone
Borsi, Ema-Cristina
Bucur, Adina
Oncu, Cristina Potre
Oncu, Ovidiu Potre
Cerbu, Bianca
Costachescu, Dan
Ionita, Ioana
Luca, Constantin Tudor
Ionita, Hortensia
REVISTA DE CHIMIE, 2019, 70 (03): : 1017 - 1022

← 1 2 3 4 5 →